Menetelmä uusien terapeuttisesti käyttökelpoisten difenyylipropyyliamiinijohdannaisten valmistamiseksi

摘要

Diphenylpropylamine derivatives of the formula I …… in which:… R<1> denotes hydrogen or methyl,… R<2> denotes hydrogen, methyl or n-decyl,… Z (a) denotes a phenyl group substituted by R<3>, R<4> and R<5>, in which:… R<3> denotes hydrogen, fluorine, chlorine or bromine, nitro, C1-12-alkyl, C1-4-alkoxy, phenoxy or benzyloxy,… R<4> and R<5> denotes hydrogen, chlorine, hydroxyl, alkoxy, benzyloxy, acetamido or carboxyl or… R<4> and R<5> together denote methylenedioxy or… (b) denotes 4-methoxynaphthyl or 4-ethoxynaphthyl, and R<6> denotes hydrogen or fluorine, with the proviso that R<1>, R<2>, R<3>, R<4>, R<5> and R<6> do not simultaneously denote hydrogen atoms,… and their physiologically tolerable acid addition salts are used as active substances in pharmaceutical agents which can primarily be advantageously used for the therapy of cardiac and circulatory disorders.